PFE · News · 20261104N
Acquisition / Partnership / Divestiture
PFIZER INC · 2026-11-04 · Importance 46 · Surprise 42 · In source text
United Therapeutics agreed to pay Pfizer subsidiary Arena Pharmaceuticals an upfront $525 million to eliminate all royalty obligations under its ralinepag license agreement. The buyout applies to all ralinepag formulations, including oral and inhaled versions, and removes a double-digit royalty payable to Pfizer on net sales. United Therapeutics remains responsible for up to $400 million in contingent regulatory milestone payments.
Key facts
- Pfizer subsidiary Arena Pharmaceuticals entered into an amendment with United Therapeutics and Arena eliminated all royalty obligations under its exclusive ralinepag license agreement in exchange for an upfront payment of $525 million. source
- The $525 million transaction eliminated the double-digit royalty payable to Pfizer on net sales of ralinepag, across oral and inhaled formulations. source
- Pfizer's adjusted diluted EPS was $0.87 in Q3 2026 and included a $0.10 charge related to the Innovent transaction. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | positive | committed | +0.2% | Pfizer subsidiary Arena Pharmaceuticals entered into an amendment with United Therapeutics and Arena eliminated all royalty obligations… |
| revenue | negative | contingent | — | The $525 million transaction eliminated the double-digit royalty payable to Pfizer on net sales of ralinepag, across oral and inhaled… |